

# Renu K Virk

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3824621/publications.pdf>

Version: 2024-02-01

13  
papers

205  
citations

1163117

8  
h-index

1125743

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

412  
citing authors

#	ARTICLE	IF	CITATIONS
1	A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. <i>Nature Cancer</i> , 2020, 1, 1082-1096.	13.2	49
2	Cooperation of loss of <i>NKX3.1</i> and inflammation in prostate cancer initiation. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	2.4	30
3	<i>NKX3.1</i> Localization to Mitochondria Suppresses Prostate Cancer Initiation. <i>Cancer Discovery</i> , 2021, 11, 2316-2333.	9.4	25
4	A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2020, 204, 247-253.	0.4	23
5	Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of <i>NKX3.1</i> Expression for Response to 5 $\alpha$ -reductase Inhibition. <i>European Urology</i> , 2017, 72, 499-506.	1.9	16
6	<i>RAD9A</i> promotes metastatic phenotypes through transcriptional regulation of anterior gradient 2 ( <i>AGR2</i> ). <i>Carcinogenesis</i> , 2019, 40, 164-172.	2.8	15
7	Impact of COVID-19 pandemic on functioning of cytopathology laboratory: Experience and perspective from an academic centre in New York. <i>Cytopathology</i> , 2021, 32, 304-311.	0.7	14
8	Targeting <i>MEK5</i> impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents. <i>Oncogene</i> , 2020, 39, 2467-2477.	5.9	11
9	The effect of tumor grade heterogeneity on recurrence in non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 60.e11-60.e16.	1.6	7
10	<i>FOXP1</i> and <i>NDRG1</i> act differentially as downstream effectors of <i>RAD9</i> -mediated prostate cancer cell functions. <i>Cellular Signalling</i> , 2021, 86, 110091.	3.6	6
11	Bladder Preservation for Patients With Bladder Paragangliomas: Case Series and Review of the Literature. <i>Urology</i> , 2020, 143, 194-205.	1.0	4
12	<i>BIA</i> ALCL diagnosis on <i>CytoLyt</i> fixed <i>ThinPrep</i> , cell block and immunohistochemistry. <i>Diagnostic Cytopathology</i> , 2022, 50, E1-E5.	1.0	3
13	The Significance of ASC-H and LSIL Dual Interpretation with Risk Stratification: One Institution Experience. <i>Journal of the American Society of Cytopathology</i> , 2021, 10, 565-570.	0.5	2